文献速递技术与安全腹部PETCT

肝脏与脂肪组织FDG摄取异常:癌症相关恶病质的潜在影像生物标志物

Abnormal [18F]FDG uptake in liver and adipose tissue: a potential imaging biomarker for cancer-associated cachexia.
PubMed 文献 · Eur Radiol · 2022-11-09

本研究基于390例癌症患者的FDG PET/CT数据,回顾性分析器官及组织特异性代谢与癌症相关恶病质的关系。发现肝脏SUV峰值、内脏及皮下脂肪瘦体重最小SUV等为独立相关因素,构建的模型在开发队列AUC为0.777,验证队列AUC为0.729。结论提示PET/CT测量的组织特异性糖代谢异常可作为癌症相关恶病质的影像生物标志物。

要点

  • 癌症相关恶病质患者肝脏FDG摄取减低,内脏脂肪和皮下脂肪FDG摄取增高。
  • 肝脏、内脏脂肪、皮下脂肪FDG摄取可作为识别恶病质的独立危险因素。
  • 结合年龄、白细胞计数及上述FDG摄取参数的模型在验证队列AUC为0.729。

核心结论

  • 基于PET/CT测量的器官和组织特异性葡萄糖代谢异常可作为癌症相关恶病质的生物标志物。

研究设计与样本

  • 回顾性分析390例癌症患者的18F-FDG PET/CT数据,分为开发队列286例和验证队列104例,以体重丢失>5%/6个月或BMI<20且体重丢失>2%定义恶病质。

关键影像表现/征象

  • 恶病质患者肝脏FDG摄取减低,内脏脂肪和皮下脂肪FDG摄取增高。

诊断标准与关键数值

  • 恶病质定义:6个月内体重丢失>5%,或BMI<20且体重丢失>2%。
  • 多因素模型纳入年龄、白细胞计数、肝脏SUV峰值、内脏脂肪和皮下脂肪瘦体重最小SUV,开发队列AUC 0.777(95%CI 0.721-0.833),验证队列AUC 0.729(95%CI 0.629-0.829)。

临床应用与阅片要点

  • 阅片时可关注肝脏及脂肪组织FDG摄取变化,结合年龄和白细胞计数辅助识别癌症相关恶病质。
  • 注意肝脏摄取减低和脂肪摄取增高可能提示恶病质状态,但需结合临床体重丢失等标准综合判断。

局限性

  • 回顾性研究设计。
  • 单中心或有限中心数据(原文未明确中心数)。
  • 样本量390例,验证队列104例,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aims to investigate and develop imaging biomarkers for the diagnosis of cancer-associated cachexia based on the organ and tissue-specific abnormal metabolisms measured by fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT.

METHODS: FDG PET/CT data from 390 cancer patients were analyzed retrospectively. Patients were divided into a development cohort and a validation cohort. Cachexia was defined as weight loss > 5% in 6 months or BMI < 20 and weight loss > 2%. According to the above definitions, patients were divided into cachexia and non-cachexia groups. Results of the clinical laboratory tests for metabolic levels and organ and tissue-specific FDG uptake obtained from the cachexia and non-cachexia groups were compared statistically. Logistic regression analysis was performed to identify independent variables associated with cachexia in the development cohort for generating the regression model. The performance of the model was tested using the data from a validation cohort and evaluated by area under the receiver operating characteristic curve (AUC).

RESULTS: Based on the data from the development cohort of 286 patients and a validation cohort of 104 patients, it is found that age, white blood cell count, peak standardized uptake value (SUV) of the liver, and minimum SUV of lean body mass of visceral fat and subcutaneous fat were independently associated with cachexia. The model incorporating these variables reached an AUC of 0.777 (95% confidence interval (CI): 0.721, 0.833) in the development cohort and an AUC of 0.729 (95% CI: 0.629, 0.829) in the validation cohort.

CONCLUSION: Organ and tissue-specific abnormal glucose metabolism as measured by PET/CT can be used as a biomarker for cancer-associated cachexia.

KEY POINTS: • Patients with cancer-associated cachexia have reduced FDG uptake in the liver and increased FDG uptake in visceral fat and subcutaneous fat. • FDG uptake of the liver, visceral fat, and subcutaneous fat can be independent risk factors for identifying cancer-associated cachexia. • Cancer-associated cachexia can be classified using the model that incorporates age, white blood cell count, FDG uptake of the liver, and visceral and subcutaneous fat can diagnose with an AUC of 0.729.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jiang, Wu, Zhao, et al. Abnormal [18F]FDG uptake in liver and adipose tissue: a potential imaging biomarker for cancer-associated cachexia. Eur Radiol. 2022. PMID: 36350393. doi:10.1007/s00330-022-09226-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。